Literatur
- 9
Cepeda JA.
Whitehouse T.
Cooper B.
Linezolid versus teicoplanin in the treatment of gram-positive infections in the critically
ill: a randomized, double-blind, multicentre study.
J Antimicrob Chemother.
2004;
53
345-355
- 10
Chamot E.
Boffi El.
Amari E.
Rohner P.
Van Delden C.
Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.
Antimicrob Agents Chemother.
2003;
47 (9)
2756-2764
- 11
Ibrahim EH.
Ward S.
Sherman G.
Schaiff R.
Experience with a clinical guideline for the treatment of ventilator-associated pneumonia.
Crit Care Med.
2001;
29
1109-1115
- 12
Iregui M.
Ward S.
Sherman G.
et al. .
Clinical importance of delays in the initiation of appropriate antibiotic treatment
for ventilator-associated pneumonia.
Chest.
2002;
122
262-268
- 13
Kaye KS.
Cosgrove S.
Harris A.
et al. .
Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter
spp.
Antimicrob Agents Chemother .
2001;
45
2628-2630
- 14
Lubasch A.
Luck S.
Lode H.
et al. .
Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe
chronic bronchitis.
Antimicrob Chemother.
2003;
51 (3)
659-664
- 15
Vincent JL.
Microbial resistance: lessons form the EPIC study. European prevalence of infection.
Intensive Care Med.
2000;
26 (suppl 1)
S3-S8
- 16
Wunderink RG.
Rello J.
Cammarata SK.
et al. .
Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant
Staphylococcus aureus nosocomial pneumonia.
Chest..
2003;
124
1789-1797
14 european prevalence of infection
